Latest / The Macro Memo with Fexingo: Daily Conversations on Inflation, GDP, and Federal Reserve Policy / How Generic Drug Tariffs Could Reshape Inflation
Transcript
- Lucas: So the headline that caught my eye today was this: the Trump administration is planning tariffs on generic drugs starting in 2028, with a two-year delay to give companies time to shift production onshore. And I think it's one of those policies that sounds straightforward on paper but gets really complicated when you poke at it. Luna: 2028 feels far off, but for pharmaceutical supply chains, that's basically tomorrow. What's the rationale here? Lucas: Right, exactly. The stated goal is to reduce reliance on China and India for generic drugs. About 80 percent of the active pharmaceutical ingredients for generics come from those two countries. The administration's argument is national security and supply chain resilience — we saw during COVID how fragile those lines were. Luna: And the two-year delay is meant to give manufacturers time to build or retool plants here. But that's a huge capital investment. Lucas: It is. And the tariffs themselves would be phased in — not a shock and awe move. But here's the tension: generic drugs are one of the few areas in healthcare where prices have actually been falling. The CPI for prescription drugs has been declining year-over-year. If you slap tariffs on imports, you risk reversing that trend. Luna: Which would feed into inflation at a time when the Fed is finally seeing some progress. Core CPI just dipped slightly to 336.1 in June, and the headline CPI is down from last month. So the timing is interesting. Lucas: Exactly. The Fed is watching every data point. And here comes a policy that could push up a category that directly affects consumers' wallets. I mean, generic drugs are the ones most people actually buy — they account for 90 percent of prescriptions filled in the US. Luna: So this is a bet that the long-term benefit of onshoring — lower supply chain risk, maybe eventually lower costs — outweighs the short-term price bump. But the question is how long that short term lasts. Lucas: Right. And there's a historical parallel. We've seen similar pushes in semiconductors with the CHIPS Act. But pharma is different. Drug manufacturing is heavily regulated by the FDA. Building a plant that meets current good manufacturing practices takes years and hundreds of millions of dollars. Luna: And the talent pool for pharmaceutical manufacturing isn't deep in the US anymore. We offshored that capability decades ago. Lucas: So you're rebuilding not just factories but an entire ecosystem. Meanwhile, the tariff could simply be passed on to consumers. The question is how much. A study from the Peterson Institute estimated that a 25 percent tariff on Chinese pharmaceuticals could raise generic drug prices by 10 to 15 percent. That's not trivial for people on fixed incomes. Luna: And the policy has a specific start date of 2028. That's after the next presidential term. So it's almost like a commitment device — a signal to industry that they have a window. Lucas: Which is smart politically. By the time the tariff hits, the current administration may not be in office. But companies have to decide now whether to invest. And if they don't, they face higher costs later. Luna: It also gives the next administration room to reverse it if they want. It's not locked in stone. Lucas: That's a good point. But I want to tie this back to the macro picture. We saw import prices post a surprise gain just last week — costs of goods from China hit their highest since 2008. So we're already seeing some upward pressure on import prices. Adding drug tariffs on top of that could nudge headline inflation higher, even if the direct weight of generics in the CPI basket is relatively small. Luna: And the Fed is currently holding the fed funds rate at 3.63 percent. They've been cutting gradually, but if inflation ticks up, they might pause. So this policy could indirectly tighten monetary conditions. Lucas: Exactly. And that's the kind of second-order effect policymakers need to consider. But the other side is: if onshoring succeeds, you could have more stable prices long term, less exposure to shipping costs, trade wars, geopolitical shocks. It's a classic short-term pain for long-term gain argument. Luna: And speaking of long-term gain — I know this is a bit meta, but it's worth saying that the reason we can have these nuanced conversations without any ad breaks is that a handful of listeners chip in monthly through Buy Me a Coffee. It's at buy me a coffee dot com slash fexingo. And that literally funds making this many episodes a week. Lucas: Yeah, it's a small group, but it makes a huge difference. Keeps the show independent and allows us to dig into exactly these kinds of policy questions without any editorial pressure. So if you've gotten something out of the show, that's the way to support it. Luna: And it's not a big ask — just knowing that people find it valuable enough to throw in a few bucks is what keeps us going. Lucas: So back to the tariffs. One more angle I want to touch on: the impact on low-income households. Generic drugs are disproportionately used by people without insurance or with high-deductible plans. A price increase there is regressive. Luna: Right. And if the tariff leads to shortages during the transition — because some foreign suppliers exit the market before domestic capacity is ready — that's a real risk. Lucas: The FDA has a shortage list, and it's already long for certain generics. So adding disruption to the supply chain could worsen that. On the other hand, if the policy actually brings production back, it could make the supply chain more resilient in the long run. Luna: It's a gamble. And the two-year delay is essentially the government saying 'we'll give you time, but we're serious.' Lucas: And the market seems to be pricing in some probability of it happening. I've seen a few analysts note that generic drug stocks have been volatile on the news. But it's still early. Luna: What about the WTO implications? Tariffs on generic drugs could face challenges. Lucas: That's another layer. The US could face retaliation or disputes. But the administration might argue national security exemptions. It's murky. Luna: So bottom line: this is a policy that could bump inflation in the near term, but with a potential payoff in supply chain security. The Fed will be watching, consumers will feel it, and the pharmaceutical industry has a big decision to make. Lucas: Exactly. And it's a perfect example of how trade policy and monetary policy intersect. We'll be tracking this one closely as more details emerge. Luna: Thanks for listening to The Macro Memo. We'll be back tomorrow.